LGND logo

Ligand Pharmaceuticals Incorporated (LGND)

$237.75

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LGND

Market cap

$4.76B

EPS

7.67

P/E ratio

31.2

Price to sales

16.75

Dividend yield

--

Beta

1.22143

Price on LGND

Previous close

$237

Today's open

$239.76

Day's range

$236.09 - $240.70

52 week range

$103.43 - $247.38

Profile about LGND

CEO

Todd C. Davis

Employees

47

Headquarters

Jupiter, FL

Exchange

NASDAQ Global Market

Shares outstanding

20041061

Issue type

Common Stock

LGND industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LGND

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share. This sale represented 10.78% of Andrew Reardon's direct Common Stock holdings, reducing direct ownership to 41,382 shares post-transaction.

news source

The Motley Fool • Jun 7, 2026

news preview

Ligand to Participate in June Investor Conferences

JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference.

news source

GlobeNewsWire • May 27, 2026

news preview

Saying Goodbye To The XOMA Royalty PFDs

Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or CVR, for 75% of net proceeds from certain pending litigation. The transaction is expected to close in Q3 2026 and be immediately accretive to LGND earnings per share.

news source

Seeking Alpha • May 25, 2026

news preview

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 9, 2026

news preview

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.

news source

MarketBeat • May 8, 2026

news preview

Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of  56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

news source

GlobeNewsWire • May 7, 2026

news preview

Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.

news source

GlobeNewsWire • May 5, 2026

news preview

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of XOMA Royalty Corporation (NasdaqGM: XOMA) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of XOMA will receive $39.00 in cash for each share of XOMA that they own. KSF is seeking to determine whether this consideration and the process.

news source

Business Wire • Apr 28, 2026

news preview

Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million

Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.

news source

WSJ • Apr 27, 2026

news preview

Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million

Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the ​companies said on Monday.

news source

Reuters • Apr 27, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ligand Pharmaceuticals Incorporated

Open an M1 investment account to buy and sell Ligand Pharmaceuticals Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LGND on M1